Login / Signup

Should daptomycin-rifampin combinations for MSSA/MRSA isolates be avoided because of antagonism?

C SteinO MakarewiczC ForstnerS WeisS HagelB LöfflerMathias W Pletz
Published in: Infection (2016)
Based on these data, there is no evidence to advise against the daptomycin/rifampin combination therapy.
Keyphrases
  • combination therapy
  • methicillin resistant staphylococcus aureus
  • staphylococcus aureus
  • electronic health record
  • big data
  • genetic diversity
  • data analysis
  • artificial intelligence
  • deep learning